









市場行情
/
股票
/
nasdaq-bhvn
/

Biohaven Ltd

BHVN

10.720USD

+0.220+2.10%

收盤 12/24, 13:00（美東）報價延遲15分鐘

1.13B總市值

虧損本益比TTM



Biohaven Ltd

10.720

+0.220+2.10%

概覽公司財務分析

概覽

公司

財務

分析

關於 Biohaven Ltd 公司

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Biohaven Ltd簡介



公司代碼BHVN

公司名稱Biohaven Ltd

上市日期Sep 23, 2022

CEOCoric (Vlad)

員工數量256

證券類型Ordinary Share

年結日Sep 23

公司地址215 Church Street

城市NEW HAVEN

上市交易所NASDAQ OMX NASDAQ Basic NYSE

國家United States of America

郵編06510

電話12034040410

網址https://www.biohaven.com/

公司代碼BHVN

上市日期Sep 23, 2022

CEOCoric (Vlad)

Biohaven Ltd公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Gregory Hugh (Greg) Bailey, M.D.

Independent Director

2.02M

+24.69%

Mr. Matthew (Matt) Buten

Chief Financial Officer

193.45K

+0.39%

Dr. Bruce Car, Ph.D.

Chief Scientific Officer

34.80K

+757.19%

Ms. Julia Paige Gregory

Independent Director

25.66K

Mr. Michael Thomas (Mike) Heffernan

Lead Independent Director

15.18K

Mr. Robert J. Hugin

Independent Director

12.96K

Dr. Irina Antonijevic, M.D., Ph.D.

Independent Director

Mr. John W. Childs

Independent Director

Dr. Vlad Coric, M.D.

Chairman of the Board, Chief Executive Officer

Ms. Kimberly Gentile

Senior Vice President of Clinical Operations

名稱

名稱/職務

職務

持股

持股變動

Dr. Gregory Hugh (Greg) Bailey, M.D.

Independent Director

2.02M

+24.69%

Mr. Matthew (Matt) Buten

Chief Financial Officer

193.45K

+0.39%

Dr. Bruce Car, Ph.D.

Chief Scientific Officer

34.80K

+757.19%

Ms. Julia Paige Gregory

Independent Director

25.66K

Mr. Michael Thomas (Mike) Heffernan

Lead Independent Director

15.18K

Mr. Robert J. Hugin

Independent Director

12.96K

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

Janus Henderson Investors

5.11%

1919 Investment Counsel, LLC

4.98%

BlackRock Institutional Trust Company, N.A.

4.94%

Childs John W

4.91%

Suvretta Capital Management, LLC

4.24%

其他

75.83%

持股股東

佔比

Janus Henderson Investors

5.11%

1919 Investment Counsel, LLC

4.98%

BlackRock Institutional Trust Company, N.A.

4.94%

Childs John W

4.91%

Suvretta Capital Management, LLC

4.24%

其他

75.83%

股東類型

持股股東

佔比

Investment Advisor

25.60%

Investment Advisor/Hedge Fund

20.43%

Hedge Fund

13.94%

Individual Investor

9.18%

Research Firm

3.29%

Sovereign Wealth Fund

0.68%

Venture Capital

0.41%

Corporation

0.38%

Pension Fund

0.35%

其他

25.75%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

573

86.14M

79.56%

+56.74K

2025Q3

585

86.08M

100.43%

-2.05M

2025Q2

570

88.15M

95.46%

-3.76M

2025Q1

560

91.76M

98.48%

-8.79M

2024Q4

552

92.88M

95.24%

+5.30M

2024Q3

538

88.35M

95.17%

+3.19M

2024Q2

505

84.45M

87.45%

+8.19M

2024Q1

484

76.13M

96.08%

-2.46M

2023Q4

433

73.36M

88.24%

+6.86M

2023Q3

386

63.55M

100.60%

+1.17M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Janus Henderson Investors

5.05M

4.78%

-1.38M

-21.51%

Jun 30, 2025

1919 Investment Counsel, LLC

6.60M

6.23%

+2.50K

+0.04%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

6.44M

6.08%

+113.23K

+1.79%

Jun 30, 2025

Childs John W

6.51M

6.15%

+351.58K

+5.71%

Mar 10, 2025

Suvretta Capital Management, LLC

5.62M

5.31%

Jun 30, 2025

State Street Investment Management (US)

3.54M

3.34%

+115.81K

+3.38%

Jun 30, 2025

Coric (Vladimir)

3.18M

+26.57K

+0.84%

Mar 10, 2025

The Vanguard Group, Inc.

9.23M

8.72%

+828.80K

+9.87%

Jun 30, 2025

Bellevue Asset Management AG

2.80M

2.65%

+762.00K

+37.34%

Jun 30, 2025

Fidelity Management & Research Company LLC

1.66M

1.57%

-246.36K

-12.89%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Neuroscience and Healthcare ETF

2.64%

Roundhill GLP-1 & Weight Loss ETF

2.18%

Simplify Health Care ETF

1.58%

Virtus LifeSci Biotech Clinical Trials ETF

0.75%

State Street SPDR S&P Biotech ETF

0.69%

Direxion Daily S&P Biotech Bull 3X Shares

0.42%

WisdomTree BioRevolution Fund

0.33%

Optimize Strategy Index ETF

0.24%

Inspire Small/Mid Cap ESG ETF

0.24%

JPMorgan Fundamental Data Science Small Core ETF

0.2%

iShares Neuroscience and Healthcare ETF

佔比2.64%

Roundhill GLP-1 & Weight Loss ETF

佔比2.18%

Simplify Health Care ETF

佔比1.58%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.75%

State Street SPDR S&P Biotech ETF

佔比0.69%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.42%

WisdomTree BioRevolution Fund

佔比0.33%

Optimize Strategy Index ETF

佔比0.24%

Inspire Small/Mid Cap ESG ETF

佔比0.24%

JPMorgan Fundamental Data Science Small Core ETF

佔比0.2%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Biohaven Ltd的前五大股東是誰？



Biohaven Ltd的前五大股東如下：
Janus Henderson Investors
持有股份：5.05M
佔總股份比例：4.78%。
1919 Investment Counsel, LLC
持有股份：6.60M
佔總股份比例：6.23%。
BlackRock Institutional Trust Company, N.A.
持有股份：6.44M
佔總股份比例：6.08%。
Childs John W
持有股份：6.51M
佔總股份比例：6.15%。
Suvretta Capital Management, LLC
持有股份：5.62M
佔總股份比例：5.31%。